Phylogenetic analysis of SARS-CoV-2 in the Boston area highlights the role of recurrent importation and superspreading events.
Journal
medRxiv : the preprint server for health sciences
Titre abrégé: medRxiv
Pays: United States
ID NLM: 101767986
Informations de publication
Date de publication:
25 Aug 2020
25 Aug 2020
Historique:
pubmed:
2
9
2020
medline:
2
9
2020
entrez:
2
9
2020
Statut:
epublish
Résumé
SARS-CoV-2 has caused a severe, ongoing outbreak of COVID-19 in Massachusetts with 111,070 confirmed cases and 8,433 deaths as of August 1, 2020. To investigate the introduction, spread, and epidemiology of COVID-19 in the Boston area, we sequenced and analyzed 772 complete SARS-CoV-2 genomes from the region, including nearly all confirmed cases within the first week of the epidemic and hundreds of cases from major outbreaks at a conference, a nursing facility, and among homeless shelter guests and staff. The data reveal over 80 introductions into the Boston area, predominantly from elsewhere in the United States and Europe. We studied two superspreading events covered by the data, events that led to very different outcomes because of the timing and populations involved. One produced rapid spread in a vulnerable population but little onward transmission, while the other was a major contributor to sustained community transmission, including outbreaks in homeless populations, and was exported to several other domestic and international sites. The same two events differed significantly in the number of new mutations seen, raising the possibility that SARS-CoV-2 superspreading might encompass disparate transmission dynamics. Our results highlight the failure of measures to prevent importation into MA early in the outbreak, underscore the role of superspreading in amplifying an outbreak in a major urban area, and lay a foundation for contact tracing informed by genetic data.
Identifiants
pubmed: 32869040
doi: 10.1101/2020.08.23.20178236
pmc: PMC7457619
pii:
doi:
Types de publication
Preprint
Langues
eng
Subventions
Organisme : NIAID NIH HHS
ID : R01 AI148784
Pays : United States
Organisme : NIAID NIH HHS
ID : R37 AI147868
Pays : United States
Commentaires et corrections
Type : UpdateIn
Déclaration de conflit d'intérêts
Competing interests: J.E.L. has received consulting fees from Sherlock Biosciences. J.B. has been a consultant for T2 Biosystems, DiaSorin, and Roche Diagnostics. A.P. is a Venture Partner at Google Ventures. P.C.S. is a co-founder and shareholder of Sherlock Biosciences, and a Board member and shareholder of Danaher Corporation.
Références
J Vis Exp. 2016 Jul 02;(113):
pubmed: 27403729
Emerg Infect Dis. 2020 Jun;26(6):1059-1066
pubmed: 32187007
Nat Med. 2020 Jun;26(6):861-868
pubmed: 32327757
Genome Biol. 2014;15(11):519
pubmed: 25403361
Science. 2020 May 8;368(6491):
pubmed: 32234805
MMWR Morb Mortal Wkly Rep. 2020 May 08;69(18):551-556
pubmed: 32379733
Clin Infect Dis. 2021 Feb 16;72(4):686-689
pubmed: 32667967
Bioinformatics. 2018 Dec 1;34(23):4121-4123
pubmed: 29790939
Genome Biol. 2004;5(10):R80
pubmed: 15461798
MMWR Morb Mortal Wkly Rep. 2020 May 15;69(19):606-610
pubmed: 32407303
N Engl J Med. 2020 May 28;382(22):2081-2090
pubmed: 32329971
Mol Biol Evol. 2015 Jan;32(1):268-74
pubmed: 25371430
MMWR Morb Mortal Wkly Rep. 2020 Apr 10;69(14):411-415
pubmed: 32271722
MMWR Morb Mortal Wkly Rep. 2020 May 22;69(20):632-635
pubmed: 32437338
Mol Biol Evol. 2013 Apr;30(4):772-80
pubmed: 23329690
Wellcome Open Res. 2020 Apr 9;5:67
pubmed: 32685698
Cell. 2015 Jun 18;161(7):1516-26
pubmed: 26091036
Lancet Infect Dis. 2020 Sep;20(9):1043-1050
pubmed: 32539988
Cell. 2020 Aug 20;182(4):812-827.e19
pubmed: 32697968
Emerg Infect Dis. 2004 Feb;10(2):256-60
pubmed: 15030693
Nature. 2005 Nov 17;438(7066):355-9
pubmed: 16292310
Lancet. 2016 Sep 3;388(10048):994-1001
pubmed: 27402381
N Engl J Med. 2020 May 21;382(21):2005-2011
pubmed: 32220208
Bioinformatics. 2011 Nov 1;27(21):3070-1
pubmed: 21926124
JAMA. 2020 May 26;323(20):2085-2086
pubmed: 32293646
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463
Virus Evol. 2016 Apr 09;2(1):vew007
pubmed: 27774300
JAMA. 2020 Jun 2;323(21):2191-2192
pubmed: 32338732
Lancet Infect Dis. 2022 Dec;22(12):e370-e376
pubmed: 36057267
Mol Ecol. 2000 Oct;9(10):1657-9
pubmed: 11050560
Genome Biol. 2019 Nov 28;20(1):257
pubmed: 31779668
JAMA. 2020 Jun 23;323(24):2466-2467
pubmed: 32391864